Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort: Validation of Decentralized Genomic Profiling.
Denkert C, Romey M, Swedlund B, Hattesohl A, Teply-Szymanski J, Kommoss S, Kaiser K, Staebler A, du Bois A, Grass A, Knappmeyer C, Heitz F, Solimeno C, Ebel T, Harter P, Marmé F, Jank P, Gaiser T, Neff C, Wagner U, Timms KM, Rodepeter F. Denkert C, et al. Among authors: jank p. J Mol Diagn. 2022 Dec;24(12):1254-1263. doi: 10.1016/j.jmoldx.2022.09.004. Epub 2022 Sep 30. J Mol Diagn. 2022. PMID: 36191839 Free article.
Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
Sehouli J, Braicu EI, Richter R, Denkert C, Jank P, Jurmeister PS, Kunze CA, Budczies J, Darb-Esfahani S, Schmitt WD, Traut A, Grabowski J, Taube ET, Plett H. Sehouli J, et al. Among authors: jank p. Hum Pathol. 2019 Mar;85:299-308. doi: 10.1016/j.humpath.2018.10.020. Epub 2018 Nov 11. Hum Pathol. 2019. PMID: 30428389
What turns CREB on? And off? And why does it matter?
Steven A, Friedrich M, Jank P, Heimer N, Budczies J, Denkert C, Seliger B. Steven A, et al. Among authors: jank p. Cell Mol Life Sci. 2020 Oct;77(20):4049-4067. doi: 10.1007/s00018-020-03525-8. Epub 2020 Apr 28. Cell Mol Life Sci. 2020. PMID: 32347317 Free PMC article. Review.
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial.
Jank P, Gehlhaar C, Bianca L, Caterina F, Andreas S, Karn T, Marmé F, Sinn HP, van Mackelenbergh M, Sinn B, Zahm DM, Ingold-Heppner B, Schem C, Stickeler E, Fasching PA, Nekljudova V, Taube ET, Heppner F, Müller V, Denkert C, Loibl S. Jank P, et al. PLoS One. 2020 Aug 25;15(8):e0238021. doi: 10.1371/journal.pone.0238021. eCollection 2020. PLoS One. 2020. PMID: 32841306 Free PMC article.
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy⋆.
Denkert C, Untch M, Benz S, Schneeweiss A, Weber KE, Schmatloch S, Jackisch C, Sinn HP, Golovato J, Karn T, Marmé F, Link T, Budczies J, Nekljudova V, Schmitt WD, Stickeler E, Müller V, Jank P, Parulkar R, Heinmöller E, Sanborn JZ, Schem C, Sinn BV, Soon-Shiong P, van Mackelenbergh M, Fasching PA, Rabizadeh S, Loibl S. Denkert C, et al. Among authors: jank p. Ann Oncol. 2021 Apr;32(4):500-511. doi: 10.1016/j.annonc.2020.12.016. Epub 2021 Jan 6. Ann Oncol. 2021. PMID: 33418062 Free article.
Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
Llop-Guevara A, Loibl S, Villacampa G, Vladimirova V, Schneeweiss A, Karn T, Zahm DM, Herencia-Ropero A, Jank P, van Mackelenbergh M, Fasching PA, Marmé F, Stickeler E, Schem C, Dienstmann R, Florian S, Nekljudova V, Balmaña J, Hahnen E, Denkert C, Serra V. Llop-Guevara A, et al. Among authors: jank p. Ann Oncol. 2021 Dec;32(12):1590-1596. doi: 10.1016/j.annonc.2021.09.003. Epub 2021 Sep 11. Ann Oncol. 2021. PMID: 34520831 Free article.
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status.
Jurmeister P, Weber K, Villegas S, Karn T, Untch M, Thieme A, Müller V, Taube E, Fasching P, Schmitt WD, Marmé F, Stickeler E, Sinn BV, Jank P, Schem C, Klauschen F, van Mackelenbergh M, Denkert C, Loibl S, Capper D. Jurmeister P, et al. Among authors: jank p. Clin Epigenetics. 2021 Oct 3;13(1):184. doi: 10.1186/s13148-021-01176-5. Clin Epigenetics. 2021. PMID: 34602069 Free PMC article.
Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict).
Jank P, Lindner JL, Lehmann A, Pfitzner BM, Blohmer JU, Horst D, Kronenwett R, Denkert C, Schmitt WD. Jank P, et al. Breast Cancer Res Treat. 2022 Jan;191(2):327-333. doi: 10.1007/s10549-021-06415-0. Epub 2021 Nov 16. Breast Cancer Res Treat. 2022. PMID: 34783927 Free PMC article.
52 results